TaiGen Reports Positive Taiwan-China Data for Novel Antibiotic

TaiGen Biotech of Taiwan reported that the IV formulation of Taigexyn ® , the company's novel antibiotic for drug-resistant infections, posted positive results in a Taiwan-China Phase III clinical trial in patients with community-acquired pneumonia. Taigexyn's oral formulation is approved in Taiwan, but the antibiotic is not yet available in China in any form. In 2012, Zhejiang Medicine paid $8 million for China rights to the Class 1.1 new drug, a novel non-fluorinated quinolone. TaiGen expects to file for China approval of the IV antibiotic in 2016. More details.... Stock Symbol: (TWO: 4157) Share this with colleagues: // //